AR125330A1 - Combinación que comprende everolimus y amcenestrant - Google Patents
Combinación que comprende everolimus y amcenestrantInfo
- Publication number
- AR125330A1 AR125330A1 ARP220100914A ARP220100914A AR125330A1 AR 125330 A1 AR125330 A1 AR 125330A1 AR P220100914 A ARP220100914 A AR P220100914A AR P220100914 A ARP220100914 A AR P220100914A AR 125330 A1 AR125330 A1 AR 125330A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- amcenestrant
- everolimus
- pharmaceutical composition
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21315063 | 2021-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125330A1 true AR125330A1 (es) | 2023-07-05 |
Family
ID=75825773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100914A AR125330A1 (es) | 2021-04-12 | 2022-04-11 | Combinación que comprende everolimus y amcenestrant |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240197692A1 (enExample) |
| EP (1) | EP4322942B1 (enExample) |
| JP (1) | JP2024516795A (enExample) |
| CN (1) | CN117177743A (enExample) |
| AR (1) | AR125330A1 (enExample) |
| ES (1) | ES3036485T3 (enExample) |
| TW (1) | TW202304424A (enExample) |
| WO (1) | WO2022218958A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3847157T3 (da) | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| WO2021063967A1 (en) | 2019-10-01 | 2021-04-08 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| CA3160897A1 (en) | 2019-12-09 | 2021-06-17 | Sanofi | Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| IL302153B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| IL302152B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4772247A2 (en) * | 2013-08-14 | 2026-07-08 | Novartis AG | Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer |
| SG11201806829TA (en) * | 2016-02-15 | 2018-09-27 | Sanofi Sa | 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators |
| EP3434272A1 (en) * | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| MX2022010425A (es) * | 2020-03-06 | 2022-09-07 | Olema Pharmaceuticals Inc | Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos. |
-
2022
- 2022-04-08 TW TW111113410A patent/TW202304424A/zh unknown
- 2022-04-11 AR ARP220100914A patent/AR125330A1/es not_active Application Discontinuation
- 2022-04-12 EP EP22722256.9A patent/EP4322942B1/en active Active
- 2022-04-12 US US18/286,496 patent/US20240197692A1/en active Pending
- 2022-04-12 JP JP2023562510A patent/JP2024516795A/ja active Pending
- 2022-04-12 CN CN202280027705.5A patent/CN117177743A/zh active Pending
- 2022-04-12 WO PCT/EP2022/059704 patent/WO2022218958A1/en not_active Ceased
- 2022-04-12 ES ES22722256T patent/ES3036485T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN117177743A (zh) | 2023-12-05 |
| EP4322942B1 (en) | 2025-04-30 |
| EP4322942A1 (en) | 2024-02-21 |
| TW202304424A (zh) | 2023-02-01 |
| ES3036485T3 (en) | 2025-09-19 |
| US20240197692A1 (en) | 2024-06-20 |
| WO2022218958A1 (en) | 2022-10-20 |
| EP4322942C0 (en) | 2025-04-30 |
| JP2024516795A (ja) | 2024-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002497A1 (es) | Uso de inhibidores de bet como tratamiento para la mielofibrosis | |
| Salazar-Mendiguchía et al. | Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist | |
| AR125331A1 (es) | Combinación que comprende ribociclib y amcenestrant | |
| JP2024516795A5 (enExample) | ||
| AR078588A1 (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
| AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata | |
| JP2024516363A5 (enExample) | ||
| JP2012503666A5 (enExample) | ||
| CO2022008437A2 (es) | Métodos de tratamiento del cáncer de pulmón de cé-lulas pequeñas con formulaciones de lurbinectedina | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| RU2015126661A (ru) | Пероральная комбинация для предотвращения и лечения патологий мочевого пузыря, органов малого таза и мочеполового аппарата | |
| de la Rubia et al. | FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies | |
| AR098745A2 (es) | Composición, kit y uso de compuestos quimioterapéuticos | |
| MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. | |
| ECSP10010011A (es) | Composición farmacéutica que comprende la combinación de diversos agentes venotónicos vasoprotectores para el tratamiento de la insuficiencia venosa crónica | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| MX2023004554A (es) | Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs. | |
| JP2019526559A5 (enExample) | ||
| MX2025014865A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib | |
| ES2395401T3 (es) | kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer | |
| KR20250167640A (ko) | 아즈부딘 및 화학요법제를 포함한 항종양 약학적 조성물 | |
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| AR041947A1 (es) | Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericas | |
| DOP2010000265A (es) | Formulacion galenica oral que comprende ketorolaco y vitaminas del complejo b, en la que la vitamina b6 se encuentra em una capa externa separada del resto de principios activos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |